CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Bionano Genomics, Inc. expected to post a loss of 49 cents a share - Earnings Preview

By Reuters News

  • Bionano Genomics, Inc. BNGO.O is expected to show a rise in quarterly revenue when it reports results on November 10 for the period ending September 30 2026

  • The San Diego California-based company is expected to report a 14.6% increase in revenue to $8.443 million from $7.37 million a year ago, according to the estimate from one analyst, based on LSEG data.The company's guidance on August 10 2026, for the period ended September 30, was for revenue between $8.20 million and $8.60 million.

  • ​LSEG's mean analyst estimate for Bionano Genomics, Inc. is for a loss of 49 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Bionano Genomics, Inc. is $5.00, about 334.8% above its last closing price of $1.15

This summary was machine generated November 7 at 00:29 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.